Ivonescimab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from hamster) |
| Target | PD-1, VEGF-A |
| Clinical data | |
| Other names | AK112 |
| Pharmacokinetic data | |
| Elimination half-life | 6-7 days |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| DrugBank | |
| UNII | |
Ivonescimab is a humanized bispecific monoclonal antibody currently being trialed for use against non-small-cell lung cancer. Developed by Akeso, it has been approved in China for the treatment of epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous NSCLC in patients who have progressed past tyrosine kinase inhibitor therapy,[1] and is undergoing clinical trials elsewhere.
Mechanism of action
[edit]Ivonescimab prevents tumor proliferation and angiogenesis by inhibiting programmed cell death protein 1 and vascular endothelial growth factor A, respectively.[2]
Research
[edit]Ivonescimab so far has only completed trials in Chinese patients,[3] and is currently undergoing phase III trials in the United States for the treatment of non-squamous non-small-cell lung cancer and advanced NSCLC.[4]
Society and culture
[edit]The initial success of ivonescimab in trials is compared to already-approved drugs such as Merck & Co.'s Keytruda (pembrolizumab); its success has been described as important for the pharmaceutical industry in China.[5]
See also
[edit]References
[edit]- ↑ "国家药监局批准依沃西单抗注射液上市". 国家药品监督管理局 (National Medical Products Administration) (in Chinese). 24 May 2024. Retrieved 6 March 2025.[dead link]
- ↑ Zhong TT, Huang ZL, Pang XH, et al. (November 2023). "1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects". Journal for Immunotherapy of Cancer. 11: A1316–A1317. doi:10.1136/jitc-2023-SITC2023.1194.
- ↑ Helwick V (25 September 2024). "HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC". The ASCO Post. Retrieved 1 March 2025.
- ↑ Dhillon S (September 2024). "Ivonescimab: First Approval". Drugs. 84 (9): 1135–1142. doi:10.1007/s40265-024-02073-w. PMID 39073550.
- ↑ Chang W, Ripley W, Cheung E (25 February 2025). "A little-known Chinese company made a drug that beat the world's biggest-selling medicine". CNN. Retrieved 1 March 2025.
External links
[edit]- Clinical trial number NCT05499390 for "AK112 in Advanced Non-Small Cell Lung Cancer" at ClinicalTrials.gov
- Clinical trial number NCT05184712 for "Phase 3 Clinical Study of AK112 for NSCLC Patients" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by adding missing information. |